EUVIMEDEUVIMED entdecken
Leitlinie

Pharmacologic Treatments of Acute Episodic Migraine Headache in Outpatient Settings: A Clinical Guideline From the American College of Physicians

Amir Qaseem iD, Jeffrey A Tice iD, Itziar Etxeandia-Ikobaltzeta iD, Timothy J Wilt, Curtis S Harrod, Thomas G Cooney, Carolyn J Crandall, Clinical Guidelines Committee of the American College of Physicians, Lauri A Hicks, Ethan Balk, J Thomas Cross, Nick Fitterman und 9 weitere

Annals of Internal Medicine · 2025-04 · 178 (4) · 571-578

DOI: 10.7326/annals-24-03095 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Annals of Internal Medicine, 2025-04. Verfasst von Amir Qaseem und 20 weiteren Autor:innen. Beteiligte Einrichtung: American College of Physicians, Philadelphia, Pennsylvania (A.Q., I.E.-I., C.S.H.). Hauptthemen laut MEDLINE: Ambulatory Care, Analgesics, Migraine Disorders. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

DESCRIPTION: The American College of Physicians (ACP) developed this guideline based on the best available evidence on the comparative benefits and harms of pharmacologic treatments of acute episodic migraine headache, patients' values and preferences, and economic evidence about these pharmacologic treatments. METHODS: This guideline is based on a systematic review and network meta-analysis of the comparative benefits and harms of pharmacologic treatments of acute episodic migraine headaches, as well as systematic reviews of patients' values and preferences and comparative cost-effectiveness analyses. The Clinical Guidelines Committee evaluated the following clinical outcomes using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach: pain freedom and pain relief at 2 hours; sustained pain freedom and sustained pain relief up to 48 hours; need for rescue medication within 24 hours; nausea, vomiting, and restored physical function at 2 hours; and overall and serious adverse events (AEs). Additional data on AEs were captured through U.S. Food and Drug Administration medication labels. AUDIENCE AND POPULATION: The audience for this clinical guideline is physicians and other clinicians. The population is adults with acute episodic migraine headache (defined as 1 to 14 headache days per month) managed in outpatient settings. RECOMMENDATION 1: ACP recommends that clinicians add a triptan to a nonsteroidal anti-inflammatory drug to treat moderate to severe acute episodic migraine headache in outpatient settings for nonpregnant adults who do not respond adequately to a nonsteroidal anti-inflammatory drug (strong recommendation; moderate-certainty evidence). RECOMMENDATION 2: ACP suggests that clinicians add a triptan to acetaminophen to treat moderate to severe acute episodic migraine headache in outpatient settings for nonpregnant adults who do not respond adequately to acetaminophen (conditional recommendation; low-certainty evidence).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ambulatory CareAnalgesicsMigraine DisordersAdultHumansAcute DiseaseAnti-Inflammatory Agents, Non-SteroidalTryptaminesNetwork Meta-Analysis as TopicSystematic Reviews as Topic

Substanzen

AnalgesicsAnti-Inflammatory Agents, Non-SteroidalTryptamines

Autor:innen und Institutionen

  • American College of Physicians, Philadelphia, Pennsylvania (A.Q., I.E.-I., C.S.H.).
  • University of California, San Francisco, San Francisco, California (J.A.T.).
  • Minneapolis VA Health Care System and the University of Minnesota Schools of Medicine and Public Health, Minneapolis, Minnesota (T.J.W.).
  • Oregon Health & Science University, Portland, Oregon (T.G.C.).
  • David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California (C.J.C.).

ORCID-Profile: Amir Qaseem, Jeffrey A Tice, Itziar Etxeandia-Ikobaltzeta

Zitieren

APA

Qaseem, A., Tice, J. A., Etxeandia-Ikobaltzeta, I., Wilt, T. J., Harrod, C. S., Cooney, T. G., Crandall, C. J., Clinical Guidelines Committee of the American College of Physicians, Hicks, L. A., Balk, E., Cross, J. T., Fitterman, N., Lewis, J., Linsky, A. M., Maroto, M., Miller, M. C., Obley, A. J., Owens, D. K., Shekelle, P. G., …, & Yost, J. (2025). Pharmacologic Treatments of Acute Episodic Migraine Headache in Outpatient Settings: A Clinical Guideline From the American College of Physicians. Annals of Internal Medicine, 178(4), 571-578. https://doi.org/10.7326/annals-24-03095

Vancouver

Qaseem A, Tice JA, Etxeandia-Ikobaltzeta I, Wilt TJ, Harrod CS, Cooney TG, et al. Pharmacologic Treatments of Acute Episodic Migraine Headache in Outpatient Settings: A Clinical Guideline From the American College of Physicians. Annals of Internal Medicine. 2025;178(4):571-578. doi:10.7326/annals-24-03095

BibTeX
@article{Qaseem2025,
  author = {Qaseem, Amir and Tice, Jeffrey A and Etxeandia-Ikobaltzeta, Itziar and Wilt, Timothy J and Harrod, Curtis S and Cooney, Thomas G and Crandall, Carolyn J and Clinical Guidelines Committee of the American College of Physicians, Clinical Guidelines Committee of the American College of Physicians and Hicks, Lauri A and Balk, Ethan and Cross, J Thomas and Fitterman, Nick and Lewis, Johanna and Linsky, Amy M and Maroto, Michael and Miller, Matthew C and Obley, Adam J and Owens, Douglas K and Shekelle, Paul G and Shamliyan, Tatyana and Yost, Jennifer},
  title = {Pharmacologic Treatments of Acute Episodic Migraine Headache in Outpatient Settings: A Clinical Guideline From the American College of Physicians},
  journal = {Annals of Internal Medicine},
  year = {2025},
  volume = {178},
  number = {4},
  pages = {571--578},
  doi = {10.7326/annals-24-03095}
}
Kostenlos starten →